* renal
** TODO Wong
- [X] List the pathological changes associated with CKD such as anemia, higher PTH level, …… 
- [X] Explain how phosphorus binding agents help CKD patients 
- [X] Describe Vd metabolism in skin, liver and kidney; distinguish active Vd from less or inactive Vd 
- [X] Explain how cinacalcet acts to reduce PTH secretion  
- [X] Explain the pharmacological concerns of use NSAIDs in patients with chronic kidney diseases
- [X] Use LMWH, furosemide, propranolol as examples to explain how kidney diseases affect drug therapy
** Lisi
- [ ] Explain the multiple physiologic functions of the kidney
- [X] Understand the role of urinalysis (chemical and microscopic) in detecting and monitoring renal disease
- [X] Recognize methods to estimate and measure creatinine clearance and GFR in patients acute and chronic renal failure
- [X] Describe the role of qualitative testing, such as CT, ultrasonography, and biopsy on renal function evaluation
- [ ] Recommend appropriate screening for microalbuminuria and/or proteinuria and evaluate the results
- [ ] Identify the signs and symptoms of kidney disease
- [ ] Recognize the Risk, Injury, Failure, Loss of Kidney Function, and End-Stage Renal Disease (RIFLE) and Acute Kidney Injury Network (AKIN) classification systems for AKI
- [ ] Categorize acute kidney injury (AKI) as prerenal, intrinsic, or postrenal based upon patient history, physical examination, and laboratory values
- [ ] List risk factors for AKI and formulate preventive strategies to decrease the risk of developing AKI in specific patient populations
- [ ] Determine appropriate management plan based upon type of AKI
- [ ] Identify indications for dialysis therapy
- [ ] Explain the advantages and disadvantages of various dialysis modalities
- [ ] Calculate the adjusted dosage regimen for a given renal-eliminated medication in a patient with AKI
* respiratory
** TODO Wong
- [X] Describe the MOA of steroids in asthma and COPD and explain why it may cause hypokalemia 
- [X] Describe the advantages of combination use of LABA with inhaled corticosteroids and the recent modification about the boxed warning about use the combination of asthma patients
- [X] Describe the MOA and side effects of SABAs and LABAs
- [ ] Compare the efficacy of LABAs, LAMAs and PDE inhibitors on asthma and COPD
- [ ] Relate the bronchiole dilators (need to know the drug names) to their receptors or enzyme target
- [X] Describe the major side effects of SAMA/SABA and LAMA/LABA
- [ ] Describe the MOA of theophyllines and Roflumilast and compare their similarity and difference
- [ ] Match the bronchodilators with their intracellular mechanisms (such as cAMP, IP3, Ca)
- [X] Describe how to affect leukotriene pathway to treat asthma 
- [X] Name the decongestants, antitussive drugs and mucolytics/expectorants and explain how they works to help COPD patients
- [X] Compare the antiinflamatory action of corticorsteroids, PDE4 inhibitors and leukotriene pathway inhibitors 
** Lisi
*** pulmonary hypertension
- [X] Explain key pathophysiologic and epidemiologic components of pulmonary arterial hypertension (PAH)
- [X] Select patients at risk for PAH and generate an appropriate approach for diagnosis
- [X] Differentiate disease severity based on World Health Organization Functional Classification
- [ ] Compare the main receptor targets for treatment strategies for PAH
- [X] Identify the non-pharmacologic treatments of PAH and their role in therapy
- [X] Recognize which pharmacotherapy for PAH requires drug access programs and why
- [ ] Design a therapeutic regimen based on overall risk: benefit considerations, including patient classification and prognostic factors
* shock
** Lisi
- [X] Define “shock”, including diagnostic parameters
- [X] Describe the three etiologies of shock and identify their common uses
- [ ] Given objective/lab information, identify the failing organ(s)
- [X] List the lab parameter that correlates to end-organ damage
- [X] Describe hemodynamic parameters and what they correlate to ysiologically
- [X] Given a hemodynamic change (CO, SVO2, CVP), identify shock iology
- [ ] Describe the different types of fluids (crystalloid vs. colloid, hypotonic vs. isotonic)
- [ ] Recommend appropriate fluid resuscitation, including fluid type and bolus dosing, given patient characteristics
- [ ] Identify vasopressors, which receptors they agonize, and the physiological effect
- [X] Describe the adverse effects of vasopressors, including extravasation management
- [ ] Given patient characteristics, recommend the appropriate vasopressor(s)
** Sharma
- [X] Define: shock state
  - List various types of shock states
  - Characteristics of shock and stages of shock
- [X] Name various crystalloids and colloids used in the management of shock
- [X] List the differences in the side effect profiles of crystalloids and colloids
- [X] Explain pharmacological mechanisms related to various agents used in shock such as positive inotropes:  
  - [X] adrenergic agents, dopamine, dobutamine and vasopressin
- [X] Major side effects associated with agents used in shock state
